Award
National Institute of Allergy and Infectious Diseases 5U01AI184071-04
Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial)
Recipient
National Institute of Allergy and Infectious Diseases (NIAID)
Award Amount
$2,832,926.00
Ceiling
$2,832,926.00
Awarded
May 07, 2026
Identifier
5U01AI184071-04
Award for a clinical trial project to improve diagnostic methods for cephalosporin allergy, including assessment of cross-reactivity and investigation of allergy mechanisms, funded by NIAID.
Description
This project aims to optimize diagnostic strategies for cephalosporin allergy, assess beta-lactam cross-reactivity, and investigate antigenic determinants and mechanisms of allergy. It involves a clinical trial with novel procedures, skin testing, and drug challenges, collaborating with drug allergy specialists. The project aligns with NIH/NIAID goals to advance drug allergy research.